Cognito Therapeutics raises $50 million for Alzheimer’s treatment tech

Cognito Therapeutics has raised $50 million in funding as it seeks to advance treatments for an elusive target: cognitive decline.

Cognito, based in Cambridge, Mass., is developing a headset that feeds a patient light and sound to drive changes in the brains of people with Alzheimer’s disease and other neurological conditions. Cognito will use the new funding from Menlo Park-based FoundersX to complete clinical trials it can submit to the Food and Drug Administration for approval. And with its new Silicon Valley connections comes a techy confidence that the company is sitting on a potential gold mine of data that could lead to a better understanding of the brain and how to treat the diseases that damage it.

“As we start to understand how patients interact with our exogenous stimulation, we’re going to build the world’s largest data set for understanding what’s necessary to personalize dose across and within patients over time,” said CEO Brent Vaughan. “And so there is the ability to build very large data network effects.”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In